Hyphens Pharma International Limited
Catalist:1J5 Voorraadrapport
Marktkapitalisatie: S$88.0m
Hyphens Pharma International Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6 Hyphens Pharma International heeft een totaal eigen vermogen van SGD69.2M en een totale schuld van SGD4.0M, wat de schuld-eigenvermogensverhouding op 5.7% brengt. De totale activa en totale passiva bedragen respectievelijk SGD131.8M en SGD62.6M. De EBIT Hyphens Pharma International is SGD15.2M waardoor de rentedekking -800.4 is. Het heeft contanten en kortetermijnbeleggingen van SGD17.9M.
Belangrijke informatie
5.7%
Verhouding schuld/eigen vermogen
Rente dekkingsratio -800.4x Contant S$17.92m Aandelen S$69.16m Totaal verplichtingen S$62.59m Totaal activa S$131.76m
Recente financiële gezondheidsupdates
Toon alle updates
Hyphens Pharma International Limited Launches Ceradan Advanced Hand Balm, Specially Designed for Hand Eczema Sep 19
Price target increased by 7.1% to S$0.38 Sep 11
First quarter 2024 earnings released May 15
Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023 Apr 26
Final dividend of S$0.0086 announced Apr 11
Hyphens Pharma International Limited, Annual General Meeting, Apr 25, 2024 Apr 09
Consensus revenue estimates increase by 10% Mar 13
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 28
Insufficient new directors Dec 01
Third quarter 2023 earnings released Nov 10
Price target decreased by 10% to S$0.34 Aug 23
Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023 Aug 12
Second quarter 2023 earnings released Aug 11 Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer Jun 06
Price target decreased by 8.9% to S$0.39 May 20
Now 23% undervalued after recent price drop May 12
Upcoming dividend of S$0.011 per share at 3.3% yield May 03
Full year 2022 earnings: EPS and revenues exceed analyst expectations Apr 11
Consensus EPS estimates increase by 14% Mar 09
Full year 2022 earnings released: EPS: S$0.037 (vs S$0.023 in FY 2021) Mar 01
Hyphens Pharma International Limited Launches its New Product, Meradan® Cream ("Meradan®") in Indonesia Dec 05
Price target increased to S$0.41 Nov 16
Insufficient new directors Nov 16
Price target increased to S$0.41 Oct 27
Consensus EPS estimates increase by 12% Aug 18
Second quarter 2022 earnings released Aug 13
Insufficient new directors Aug 02
Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2021, Payable on 25 May 2022 Apr 28
Price target decreased to S$0.35 Apr 27
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 15 Hyphens Pharma International Limited, Annual General Meeting, Apr 27, 2022
Hyphens Pharma International Limited Recommends Final Tax Exempt (1-Tier) Dividend for the Financial Year Ended December 31, 2021 Feb 24
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 24
Price target decreased to S$0.35 Feb 02
Third quarter 2021 earnings released: EPS S$0.004 (vs S$0.003 in 3Q 2020) Nov 16
First quarter 2021 earnings released: EPS S$0.007 (vs S$0.007 in 1Q 2020) May 14
Hyphens Pharma International Limited Approves Final Exempt (One-Tier) Dividend for the Year Ended 31 December 2020, Payable on 25 May 2021 Apr 29
Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019) Apr 18
Full year 2020 earnings released: EPS S$0.021 (vs S$0.022 in FY 2019) Feb 28
Revenue and earnings miss expectations Feb 28
Hyphens Pharma International Limited Appoints Exclusive Distributor in South Korea for Tdf Fairence T-Complex Jan 20
New 90-day low: S$0.32 Dec 10
Price target lowered to S$0.38 Nov 17
New 90-day low: S$0.34 Nov 12
Hyphens Pharma International Limited Announces Board Changes Nov 06
Analysts update estimates Aug 21
First half earnings released Aug 14
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( SGD101.6M ) 1J5 } overtreffen de korte termijn passiva ( SGD57.7M ).
Langlopende schulden: De kortetermijnactiva 1J5 ( SGD101.6M ) overtreffen de langetermijnschulden ( SGD4.9M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 1J5 heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van 1J5 is de afgelopen 5 jaar gestegen van 1.1% naar 5.7%.
Schuldendekking: De schuld van 1J5 wordt goed gedekt door de operationele kasstroom ( 75.6% ).
Rentedekking: 1J5 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}